GLP-1 medications such as Ozempic, Wegovy and Mounjaro have dominated headlines in recent years for their significant potential in helping individuals with weight-loss. However, recent studies are showing that they may be beneficial for more than just weight-loss, and may actually play a significant role in reducing inflammation and tissue damage. A new study published in Cell Metabolism found that semaglutide (a GLP-1) may help alleviate osteoarthritis related inflammation and tissue damage including cartilage destruction, osteophyte formation and pain sensitivity, independent of weight loss. GLP-1 induced weight loss is an additive feature, which also independently helps reduce inflammation and improve healing. While more research and larger scale studies need to be done, these results indicate a positive new arena for this line of therapeutics.
Research indicates that nearly 530 million people worldwide are impacted by osteoarthritis. Often, obesity contributes to this problem significantly, as excessive body weight can create increased wear and tear on joints and also lead to metabolic syndrome, thereby slowing the healing process and increasing chronic inflammation. Therapeutics for chronic arthritis often include NSAIDs, steroid injections directly into the site, or pain medications; however, lifestyle changes including weight loss and increased exercise are among the most long-lasting and sustainable.
Therefore, the dual impact of these medications and their effects in both reducing weight as well as chronic inflammation holds immense potential for individuals. Unfortunately, however, these medications are not incredibly easy to access for the vast majority of patients. Price is one of the most notorious bottlenecks, as GLP-1 injections can range anywhere from a few hundred to a few thousand dollars per month. Fortunately, many policy makers and companies are attempting to democratize access further in the coming years; in fact, there are active efforts underway to ascertain how individuals can get these medications covered with insurance. The Centers for Medicare and Medicaid Services (CMS) has also recently launched a Medicare GLP-1 Bridge program, aimed at providing individuals with increased access. Specifically, the program entails “a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.” More details are forthcoming on the program, especially as part of a larger and wider scoped initative for the decade ahead: “The future of Medicare coverage hinges on something called the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) model, which will attempt to integrate GLP-1s into the standard benefit package more permanently.”
Indeed, this remains one of the most important conversations taking place in medicine currently. As the American Medical Association has stated, “The costs for the patient and broader health care system associated with obesity, including the treatment of weight-related conditions and potential complications, can be substantial. It is crucial to recognize the urgency of addressing this disease comprehensively and proactively through a range of suitable treatments.” Especially given the downstream impacts of metabolic syndrome and other chronic illnesses, there is true urgency in furthering the research and access to these potentially hallmark medications.
